Secondary analysis of five trials of investigational mosaic HIV-1 vaccines: vaccine-induced seropositivity on HIV antibody tests persisted in 91% (50/55) at 6.5 years in one trial and reached 100% by study end in the other four; a single negative test was unreliable.
Secondary analysis
Callewaert et al. Vaccine-induced seropositivity/seroreactivity (VISP/R) on common HIV screening assays after vaccination with investigational adenovirus vector-based mosaic HIV regimens in clinical trials